Skip to main content
. Author manuscript; available in PMC: 2023 Nov 2.
Published in final edited form as: ACS Chem Neurosci. 2022 Oct 24;13(21):3118–3125. doi: 10.1021/acschemneuro.2c00525

Figure 1.

Figure 1.

Time–concentration profiles of uPSEMs and metabolites. Levels of uPSEM817 (pink) and metabolites, hydroxyvarenicline (orange) or varenicline (green), in plasma (A) and CSF (B) after an intravenous (i.v.; triangle with dashed line; n = 2 rhesus monkeys) or subcutaneous (s.c.; square with solid line; n = 5 rhesus monkeys) administration of 0.064 mg/kg dose of uPSEM817. Panels C and D illustrate the levels of uPSEM792 (blue) and metabolites in plasma (C) and CSF (D) after i.v. or s.c. administration of 0.87 mg/kg dose of uPSEM792 in two rhesus monkeys.